Radiation plus immunotherapy shows promise against aggressive brain tumor
NCT ID NCT02866747
First seen Apr 20, 2026 · Last updated Jun 07, 2026 · Updated 7 times
Summary
This study tested a new treatment for glioblastoma, a fast-growing brain cancer that had come back after initial therapy. The treatment combined a precise, high-dose radiation technique with an immunotherapy drug called durvalumab, which helps the immune system attack cancer cells. The goal was to see if this combination was safe and could help patients live longer. The trial involved 108 adults with recurrent glioblastoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Francois Baclesse
Caen, 14 000, France
-
Centre Georges Francois Leclerc
Dijon, 21 000, France
-
Centre Paul Strauss
Strasbourg, 67000, France
-
Hopital Avicenne
Bobigny, 93 000, France
-
Hopital Pitie Salpetriere
Paris, 75013, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Saint-Cloud, 92 210, France
-
Institut Gustave Roussy
Villejuif, 94 800, France
-
Institut Regional Du Cancer de Montpellier
Montpellier, 34 298, France
-
Institut de Cancerologie de L'Ouest
Angers, 49055, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.